Maribavir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Maribavir: From Cytomegalovirus (CMV) Infection to Bronchitis
One-Sentence Summary
Maribavir is an antiviral agent (a UL97 protein kinase inhibitor) established for cytomegalovirus (CMV) infection. The TxGNN model predicts a possible link to Bronchitis, but this prediction is currently supported by 0 clinical trials and 0 publications — it reflects knowledge-graph topology only, with no clinical or mechanistic corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack (data gap — DG002). Supporting rationale text identifies Maribavir as a UL97 protein kinase inhibitor active against cytomegalovirus (CMV); this has not been independently verified against a structured indications field |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 87.79% |
| Evidence Level | L5 |
| Australia Market Status | Not currently marketed in Australia |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as data gap DG002, High severity). Based on the accompanying rationale text, Maribavir acts as a UL97 protein kinase inhibitor, primarily blocking CMV DNA packaging and nucleocapsid egress — a mechanism specific to cytomegalovirus replication.
Bronchitis is typically caused by other respiratory viruses or bacteria, not CMV, and there is no established pharmacological pathway connecting UL97 kinase inhibition to bronchial inflammation. The TxGNN score of 87.79% reflects graph-embedding proximity between the drug and disease nodes rather than any demonstrated biological or clinical relationship.
The remaining nine predicted indications for Maribavir in this evidence pack (diabetic retinopathy, bronchial/colonic/cecal neoplasms, filariasis, etc.) show the same pattern — no mechanistic rationale, no trials, and no literature — suggesting this drug’s overall prediction set is driven by graph topology rather than biological signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
No ARTG entries found. Maribavir is not currently marketed in Australia (0 licenses on file).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. Note: TFDA/TGA-equivalent warnings and contraindications could not be retrieved for this evaluation (data gap DG001, flagged as Blocking — this prevents progression to the S1 safety pre-assessment stage), and no drug-drug interaction data was found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by TxGNN topology (L5, Decision Stage S0) with no clinical trials, literature, or plausible mechanistic link to bronchitis. A blocking data gap in TFDA/TGA safety labelling also prevents any safety pre-assessment.
To proceed, the following is needed:
- TGA-approved Product Information (warnings, contraindications) — currently blocking (DG001)
- Verified original indication and mechanism-of-action data (DG002)
- Preclinical or mechanistic studies establishing biological plausibility for bronchitis
- Any early clinical or case-level evidence before this candidate can move beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.